ArticleCancer immunology research2022

Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab.

Kent Thudium et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.